Search bioRxiv⌕ Search

Biology subjects

Denom, J.

Publications and source records attributed to Denom, J..

3 recordsLinked to original sources

Serine palmitoyltransferase-mediated de novo sphingolipid biosynthesis is required for normal insulin production and glucose tolerance

Aims/HypothesisThe importance for normal insulin secretion of ceramide synthesis is unclear. De novo ceramide synthesis requires serine palmitoyl transferase, SPT2, encoded by Sptl2. MethodsWe generated {beta}-cell-selective Sptl2 null mice by crossing animals with floxed alleles to mice expressing Cre recombinase from the Ins1 locus. Metabolic phenotyping, transcriptomic, functional analyses and histology were performed using standard approaches. ResultsIslets from Sptlc2{Delta}Ins1 mice displayed marked alterations in ceramide and sphingomyelin levels: ceramide content: p=0.016 and p=0.109; sphingomyelin content: p=0.016 and p=0.004 in Sptlc2{Delta}Ins1 vs Sptlc2CTL mice under regular and high fat diet, respectively, despite compensatory increases in the expression of enzymes in the salvage and sphingomyelinase pathways. Correspondingly, profound abnormalities were observed in glucose-regulated insulin secretion and glucose tolerance in vivo, both on a regular chow and high fat diet. These changes were associated with a drastic ([~]80%) lowering in {beta}-cell numbers, and a more minor increase in delta cell numbers. They were also preserved in animals maintained on a ketogenic diet, consistent with a cell autonomous effect on the {beta}-cell. Despite normal glucose-regulated intracellular calcium dynamics and insulin secretion, marked transcriptomic changes were observed in Sptlc2{Delta}Ins1 mouse islets, with affected GO terms including lysosome organisation and regulation of autophagy. Consistent with roles for compromised SPT2 function in diseased {beta}-cells, Sptl2 expression in Balbc and DBA2J mouse islets was lowered by a high fat-diet. Moreover, SPTLC2 mRNA tended to be lower, and SPTLC1 mRNA was significantly decreased, in islets from human subjects with type 2 diabetes versus normoglycemic individuals. ConclusionsPreserved de novo ceramide synthesis is required to maintain normal {beta}-cell mass and thus insulin secretion in mice. Therapeutic approaches which seek to target this process systemically using pharmacological SPT2 inhibitors should thus be treated with caution. Research in contextO_ST_ABS- What is already known about this subject?C_ST_ABSCeramides are key components of sphingolipid metabolism. Excess ceramide levels contribute to lipotoxicity and {beta}-cell apoptosis. -cell-restricted deletion of Cers2, which is responsible for the synthesis of very long ceramide chains, alters the insulin content of pancreatic islets and modifies glucose tolerance. Deletion of Cers 5 or 6, responsible for the synthesis of the long chains, has no effect. - What is the key question?What is the importance of de novo ceramide synthesis in {beta}-cells for the normal regulation of insulin production and glucose homeostasis? - What are the new findings?Inhibition of the de novo ceramide synthesis pathway in {beta}-cells, achieved by selective deletion of Sptlc2, encoding subunit 2 of the serine palmitoyltransferase (SPT) enzyme, induces a major alteration of glucose tolerance and insulin secretion. This is accompanied by a drastic reduction in {beta}-cell mass and islet insulin content. The remaining islets of Sptlc2{Delta}Ins1 display normal glucose-regulated intracellular calcium dynamics and insulin secretion despite imbalances in ceramide and sphingomyelin levels and substantial transcriptomic changes. Expression of SPTLC1, which encodes the other subunit of the SPT heterodimer, is reduced in islets from humans with type 2 diabetes, and a trend is observed towards lowered SPTLC2 expression. Taken together, these findings highlight the importance of de novo ceramide synthesis for normal {beta}-cell survival and function - How might this impact on clinical practice in the foreseeable future?By suppressing insulin production, global blockade or inhibition of SPT2, achieved with pharmacological approaches which seek to rescue insulin sensitivity in T2D, may be deleterious for glucose tolerance.

physiology↗

The GLP-1 analogue, exendin-4, improves bone material properties and strength through a central relay in ovariectomized mice

Glucagon-like peptide-1 (GLP-1) has previously been shown to be indispensable for optimal bone strength by acting at the bone material level. However, it was not fully clear whether the effects of GLP-1 were mediated by direct or indirect actions on bone cells. In the present study, we were unable to demonstrate the expression of the GLP-1 receptor (GLP-1r) in bone tissue at the gene expression level using qPCR and in situ hybridization, or at the protein level. Furthermore, the peripheral administration of exendin-4, a specific GLP-1r agonist, in ovariectomized (OVX) BALB/c mice enhanced post-yield displacement (18%) and energy-to-fracture (24%), as well as bone volume/total volume (BV/TV) (11%), trabecular number (Tb.N) (6%), and collagen maturity (18%). These bone effects were still observed when exendin-4 was centrally administered into the lateral cerebral ventricle. On the other hand, the peripheral administration of exendin-4 coupled to bovine serum albumin, a GLP-1r agonist that cannot penetrate the brain, failed to replicate the positive effects on bone despite increased calcitonin secretion. Altogether, these data confirm that GLP-1r agonists represent an interesting approach for managing bone fragility due to ovariectomy, but also suggest that GLP-1r agonists require a central relay yet to be identified to exert positive effects on bone physiology. Further studies are needed to decipher the mechanisms of action of GLP-1 and GLP-1r agonists on bone physiology.

physiology↗

A neuronal circuit driven by GLP-1 in the olfactory bulb regulates insulin secretion

Glucagon-like peptide 1 (GLP-1) stimulates insulin secretion and holds significant pharmacological potential. Nevertheless, the regulation of energy homeostasis by centrally-produced GLP-1 remains partially understood. Preproglucagon cells, known to release GLP-1, are found in the olfactory bulb (OB). We demonstrate that activating GLP-1 receptors (GLP-1R) in the OB stimulates insulin secretion in response to oral glucose in lean and diet-induced obese mice. This is associated with reduced noradrenaline content in the pancreas and blocked by an 2-adrenergic receptor agonist, highlighting the functional implication of the sympathetic nervous system (SNS). Inhibiting GABAA receptors in the paraventricular nucleus of the hypothalamus (PVN), the control centre of the SNS, abolishes the enhancing effect on insulin secretion induced by OB GLP-1R. Therefore, OB GLP-1-dependent regulation of insulin secretion relies on a relay within the PVN. These findings identify a novel top-down neural mechanism engaged by OB GLP-1 signaling to control insulin secretion via the SNS.

physiology↗